Navigation Links
Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division
Date:2/8/2010

LAWRENCEVILLE, N.J., Feb. 8 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced today that Michael H. Richardson has joined the company as Vice President, Commercial Operations for the newly formed Orphan Drug Business Unit. Donald A. Fishbein assumes the same role for the Ophthalmic Business Unit. A wholly owned subsidiary of Princeton Pharma Holdings LLC, Aton is focused on the development and commercialization of unique products in ophthalmology and orphan diseases.

Mr. Richardson holds responsibility of the company's orphan drug portfolio, which includes well-established specialty pharmaceuticals treating a range of rare and life-threatening conditions (Mephyton®, Edecrin®, Sodium Edecrin®, Cuprimine®, Syprine®, Demser®).  

Mr. Richardson possesses nearly 20 years of experience in pharmaceutical marketing, sales, product planning and business development. Prior to joining Aton, he was a Group Director of Marketing and Senior Director of Worldwide Product Planning for Cephalon. In those roles, Mr. Richardson was responsible for the successful launch of multiple products.

"With both product and corporate management experience, Michael Richardson brings tremendous commercial leadership to Aton Pharma," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "He is well rounded in all aspects of pharmaceutical marketing and preparing new products for launch. This experience will provide tremendous value to the company as we expand our orphan drug portfolio."

Prior to Cephalon, Mr. Richardson was a Director of Global Strategic Marketing at Johnson & Johnson where he worked on optimizing the life cycle of several strategic products. Also at Johnson & Johnson he served in New Product Planning. Prior to Johnson & Johnson, Mr. Richardson was in Sales for Merck & Co., Inc. He holds a B.A. degree in Chemistry from West Virginia University and a M.B.A. from the Fuqua School of Business at Duke University.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of products, with sales in over 30 countries, focuses on ophthalmic diseases and orphan conditions. For more information, see www.atonrx.com.

SOURCE Aton Pharma, Inc.

RELATED LINKS
http://www.atonrx.com

'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance
2. Octapharma Accepting Applications for Research Grants Through March 31
3. Two Long-Term Care Organizations Select Remedi SeniorCare for Pharmacy Services
4. Possible pharmacological target(s) identified in pediatric OSA
5. Six Key Areas of Learning for Pharmaceutical and Healthcare Marketing in 2010
6. Frost & Sullivan Ghanaian Pharmaceutical Industry Innovation & Advancement Award Conferred on LaGray Chemical Company
7. Viscira Expands Interactive Solutions to Reduce Marketing Expenses for Pharmaceutical Companies in Challenging Economic Times
8. Nutra Pharma Announces Fourth Quarter Sales for its Over-the-Counter (OTC) Pain Reliever, Cobroxin
9. Pharmalink Regulatory Affairs Consulting Firm Opens New Offices in Washington, DC and Hartford, CT
10. Therapure Biopharma Inc. signs multi-year manufacturing agreement with LFB Biomedicaments
11. Standard Methods Miss 50% of Pharmaceutical Key Opinion Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer ... physician colleagues, skilled nursing facility medical directors and other clinicians at various events ... Care." , "At many of these conferences we get to educate other physicians, ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology: